Early-stage angel investor Karna D Shinde has invested in the medical technology company neuro42. This is the third round of investment by Shinde in the company, according to a statement.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

nuero42, a medical tech startup in the neurosurgery field, intends to specialises in imaging the brain and head, with an emphasis on MR-guided therapies. One of neuro42's key motivations of innovation is its ability to enhance neurosurgeons' capabilities in complex and time-sensitive procedures like brain tumor and epilepsy therapy.

Karna D Shinde has been an early investor in neuro42 and has been directly involved with the company since its inception and has consistently supported neuro42's objective to improve neuroimaging and therapies.

"The diagnostic and interventional capabilities of neuro42's MRI have the potential to transform the way challenging brain tumor cases are approached and treated," said Karna D Shinde.

The neuro42 MRI system's compact and portable design increases its utility in clinical settings, providing healthcare providers with flexibility and convenience. The capacity to do imaging and interventions with interventional MRI can greatly reduce treatment delays and enhance overall neurosurgical efficiency.

Neuro42 MRI is receiving favorable response and has sparked significant interest from healthcare facilities in several Indian states, including Telangana, Maharashtra, and Karnataka. The fact that neuro42 has received USFDA authorization is a big milestone for the company.

This approval not only certifies the quality and safety of neuro42 MRI technology, but also enables the company to extend its operations and service a bigger market, which benefits healthcare facilities, patients, and the company.